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Introduction: Psoriasis is a chronic inflammatory skin disease affecting approximately 2% 
to 3% of the population worldwide. Discoveries over the past 3 to 5 years have significantly 
altered our view of psoriasis as primarily a T-cell mediated condition. The most recent research 
has demonstrated the essential role of specific cytokines in the development of this complex 
disease, including TNF-α, interleukin-23 (IL-23), and potentially, IL-22. These are all part of a 
newly defined autoimmune pathway directed by specialized T cells called Th17 helper T cells. 
Ustekinumab is a fully human monoclonal antibody that targets IL-12 and IL-23, thus targeting 
both Th1 and Th17 arms of immunity. It has a promising efficacy and safety profile that not only 
represents a valuable treatment alternative, but also a continuation in our constantly evolving 
understanding of this disorder.
Aims: To review the emerging evidence supporting the use of ustekinumab in the management 
of moderate to severe plaque psoriasis.
Evidence review: There is clear evidence that ustekinumab is effective in the treatment of 
moderate to severe psoriasis. Phase III trials (PHOENIX 1 and 2) demonstrated a statistically 
significant difference between Psoriasis Area and Severity Index (PASI) 75 responses achieved 
by patients receiving ustekinumab, given as a 45 mg or 90 mg subcutaneous injection every 
12 weeks, than their placebo counterparts. Treatment with this novel agent resulted in a rapid 
onset of action, with over 60% of treated patients attaining Physician’s Global Assessment 
(PGA) scores of “cleared” or “minimal” by week 12. Quality of life assessments paralleled 
clinical improvements.
Clinical potential: Ustekinumab is an effective and efficient therapeutic option for patients with 
moderate to severe psoriasis. Although further studies are required to establish ustekinumab’s 
place in the therapy of psoriasis, with its convenient dosing schedule and rapid onset of action, 
this drug could provide a great addition to the current therapeutic armamentarium available 
for psoriatic patients.
Keywords: ustekinumab, psoriasis, biologics, interleukin-12 (IL-12), interleukin-23 (IL-23), 
IL-12/23, evidence
Core evidence outcomes summary for ustekinumab in psoriasis
Outcome  
measure
Evidence Implications
Disease-oriented evidence
Statistically significant  
PASI 75 responses
Clear Ustekinumab effectively controls psoriasis 
and improves clearance rates compared 
to placebo
(Continued)
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Scope, aims, and objectives
Ustekinumab (Stelara®; Centocor, Inc), previously 
referred to as CNTO 1275, is a fully human monoclonal 
antibody that targets interleukin-12 (IL-12) and interleu-
kin-23 (IL-23). It binds with high affinity to their shared 
p40 subunit, neutralizing their bioactivity by blocking 
interactions with their cognate receptors. This review seeks 
to assess the emerging evidence for ustekinumab in the 
management of psoriasis.
Methods
English language literature searches were conducted on 
January 1st, 2009 in the following databases, searching from 
the beginning of the database to current date unless otherwise 
stated. The search strategy was “ustekinumab AND psoriasis” 
and “CNTO 1275 AND psoriasis”:
•    PubMed, http://www.ncbi.nlm.nih.gov/pubmed. Limits 
imposed for specificity: “English,” “clinical trial,” “meta 
analysis,” “randomized controlled trial,” “humans”
•  EMBASE, http://www.embase.com
Table 1 Evidence base included in the review
Category Number of records
Full papers Abstracts
Initial search 3 0
Additional papers identified 1 (comment) 0
Search update, new records 1 0
Level 1 clinical evidence 0 0
Level 2 4 0
Level  3 0 0
Economic evidence 0 0
Total records included 4 0
•   National Guideline Clearinghouse, http://www.
guideline.gov
•    Cochrane Database of Systematic Reviews (CDSR), 
http://www.cochrane.org
Following the search, a total of three full papers were 
included in the evidence base, one phase II trial and two 
phase III trials. The search on PubMed was updated on 
June 1st, 2009. One new record was identified and included 
in the review (a phase II trial). The selected records are sum-
marized in Table 1.
Disease overview
Psoriasis is a chronic inflammatory skin disease affecting 
approximately 2% to 3% of the population worldwide.1,2 
Characterized by well-demarcated itchy red, scaly plaques, it 
can present with a wide clinical variability. Plaque-type is the 
most common form (and the one we will refer to throughout 
Table 2 Established treatment options for psoriasis
Category Treatment
Topical Corticosteroids
Vitamin D analogs
Tars
Others (anthralin, salicylic acid, retinoids)
Systemic
Phototherapy UVB
PUVA
Conventional Methotrexate
Cyclosporine A
Acitretin
Biologics Alefacept
Adalimumab
Etanercept
Infliximab
(Continued)
Outcome  
measure
Evidence Implications
Time to relapse Substantial The median time to loss of PASI 75 after 
withdrawal was about 15 weeks
Patient-oriented evidence
Quality of life  
improvement
Clear Ustekinumab considerably improves 
quality of life in psoriatic patients 
compared to placebo
Tolerability Moderate Safety profile similar to other biologics. 
Further studies are required to evaluate 
long-term tolerability
Economic evidence
Cost effectiveness No evidence
Abbreviations: PASI, Psoriasis Area and Severity Index.Core Evidence 2010:5 13
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this review), but other forms include guttate, pustular, and 
erythrodermic.
Discoveries over the past 3 to 5 years have significantly 
altered our view of psoriasis as primarily a Th1 mediated 
condition. The most recent research has demonstrated the 
essential role of specific cytokines in the development of 
this complex disease, including tumor necrosis factor alpha 
(TNF-α), IL-23, and, potentially, IL-22. These are all part of 
a newly defined autoimmune pathway directed by specialized 
T cells called Th17 helper T cells.3,4
This multisystemic disorder, primarily affecting the skin 
and joints (psoriatic arthritis) is associated with several comor-
bidities, including inflammatory bowel disease, lymphoma, 
coronary heart disease, obesity, and metabolic syndrome.5–8 
There is a significant emotional burden on these individuals, 
and psychiatric/psychological comorbidities such as depres-
sion, suicidal ideation, and other mood disorders, have also 
been linked.9–12 The negative impact of psoriasis on patients is 
comparable to that of heart disease, cancer, and arthritis.13,14
The cause of psoriasis remains unknown. However, link-
ages to various genetic traits have been identified, as well 
as a myriad of environmental factors that trigger/exacerbate 
the condition.15–17 Our knowledge on the pathophysiology of 
psoriasis has been furthered deepened during the last decade. 
Previously considered a disorder of keratinocyte hyperprolif-
eration, it is now understood that its clinical manifestations 
are secondary to a complex interplay between immune cells, 
skin cells and dermal endothelium, and the interactions of 
their pro-inflammatory cytokines, chemokines and various 
chemical mediators.18
The new psoriasis model is explained by the interaction 
between epidermal keratinocytes and various immunocytes, 
including the four different CD4+ subsets: Th1, Th2, Th17, 
and T-regs.18 Recently discovered Th17 cells form part of a 
pathway mainly regulated by IL-23 (among several cyto-
kines), and have been associated with regulation of autoim-
munity.3 Although initial experiments were targeted towards 
IL-12’s p40 subunit, serendipitous findings suggested that 
IL-23 (which shares a common p40 subunit with IL-12) was 
more important in the psoriasis immunopathogenesis, shifting 
the paradigm to a Th1/Th17 hypothesis.19,20
In the cytokine model (Figure 1), sentinel cells in 
symptomless skin start producing IL-23 secondary to an 
unknown stimulus, and possible TNF.21 It is important to 
highlight that these sentinel cells, previously considered to be 
macrophages and resident dermal dendritic cells (DCs), are 
currently considered by many investigators to be a different 
population of DCs that appear during inflammation, called 
“inflammatory” dermal DCs. This subset, characterized by 
CD11c+ and CD1c/BCDA-1-, are increased significantly in 
psoriatic skin in comparison to the other dermal DCs popula-
tions, and they are thought to contain an even more special-
ized DCs subset that has the ability to produce mediators 
like TNF and intracellular nitric oxide synthase.22 The later 
have been termed TIP-DCs (TNF and inducible nitric oxide 
synthase producing DCs), and are held accountable for the 
production of IL-23.23
In turn, IL-23 sustains Th17 proliferation, hence primarily 
increasing levels of IL-17 and IL-22 produced by these acti-
vated Th17 cells (It has been suggested that Th0 differentia-
tion into Th17 is originally initiated by IL-6 and TGF-β, and 
then supported by IL-23 and TNF-α). Further downstream, 
IL-20 and IL-22 have the ability to induce keratinocyte pro-
liferation and epidermal remodeling through phosphorylation 
of Stat3, a transcription factor implicated in psoriasis.19,24 In 
contrast, IL-12 is associated with the Th1 arm. Through it, 
IL-12 promotes proliferation of IFN-γ-producing Th1 cells, 
which have been associated with regulation of cell-mediated 
immunity. Th1 cells also secrete TNF-α, further contributing 
to inflammation and development of psoriatic plaques.18,25,26
Additional data support the role of IL-12 and IL-23 in 
psoriasis, when genetic studies found associations between 
certain polymorphisms of the IL-12 receptor (IL-12R) 
and IL-23R genes and psoriasis.27 It is noteworthy that the 
sequences/processes depicted above portray a simplified ver-
sion of what is rather a very complex and intricate model.
Different parameters have been used to estimate the sever-
ity of the disease, as well as to evaluate clinical outcomes of 
therapeutic agents.28 Among the most widely accepted, and for 
the purposes of this review, we will list the Psoriasis Area and 
Severity Index (PASI), Physician’s Global Assessment (PGA), 
Total Body Surface Area (TBSA), and the Dermatology Life 
Quality Index (DLQI). The PASI is currently regarded as one 
of the most reliable and consistent outcome measures, thus is 
commonly used in clinical studies.29 It is a composite index, 
ranging from 0 to 72, that assigns a score to the three main 
characteristics of a psoriatic plaque (erythema, thickness and 
scaling, scored from 0 to 4), weighted by its extension on the 
four main body areas (head, trunk, upper extremities, and 
lower extremities). Higher PASI scores are associated with 
more severe disease.30 Improvements in PASI of 50%, 75%, 
and 90% (PASI 50, 75, and 90, respectively) are often used 
as clinical outcomes.
Traditionally, the PGA is used in the clinical practice. This 
method classifies the psoriasis as clear (0), minimal (1), mild 
(2), moderate (3), severe (4), or very severe (5), depending Core Evidence 2010:5 14
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on the quality and extension of the psoriatic lesions. TBSA 
ranges from 0 to 100% depending on the surface affected. 
The DLQI, a patient-reported outcome, is a 10-item question-
naire completed by the patients that measures the impact of 
psoriasis on their quality of life. It can go from 0 to 30, with 
higher scores indicative of poor quality of life.29
An integral assessment is necessary to label with accuracy 
the severity of the psoriasis in each individual, and therefore 
select the appropriate treatment modality based on this result. 
By joining physician-reported and patient-reported outcomes, 
the clinician might estimate the actual toll of psoriasis, not 
only in their patient’s body, but also on their psyche.
Current therapy options
Psoriasis management depends on various factors, such as 
clinical variant, extension, severity, presence of psoriatic 
arthritis, and comorbidities; ranging from local modalities up 
to systemic regimens.31 All the available options are directed 
Stimulus
TIP-DC
CD11c+
CD1c/BDCA−1−
IL-23
IL-6
IL-17
Th0 Th17
IL-22
TNF-α
Stat3 active keratinocytes
Keratinocyte hyperproliferation
and epidermal thickening
Figure 1 Th17 pathway. TIP-dendritic cells (TIP-DCs), secondary to a stimulus, produce IL-23 and TNF-α, which sustain differentiation of Th precursors into Th17 cells (originally 
initiated by IL-6 and TGF-β). As a result, activated Th17 cells secrete IL-17 and IL-22, resulting in keratinocyte hyperproliferation and plaque formation.19Core Evidence 2010:5 15
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towards sign/symptom relief, and none of them represent a 
cure for this chronic illness. A list of established treatment 
options for psoriasis is shown in Table 2.
The most overall used treatments are topical corticoste-
roids, which are broadly accessible as mild over-the-counter 
and much stronger prescribed preparations.32 Very effica-
cious and safe, their use is appropriate for localized disease, 
but is limited by convenience (eg, frequency of application, 
messiness, greasy feeling, etc), long-term use side effects 
(eg, skin atrophy), and impracticality for more than local-
ized disease.33 A recent study by Strowd et al revealed that 
from 1986 to 2005, there were an estimated 23.9 million 
visits for psoriasis management in the US, including both 
dermatologists and other physicians’ visits. During the 
20-year period, topical corticosteroids were the most com-
monly prescribed psoriasis medication, with more potent 
versions prescribed in recent years. Other popular topical 
alternatives include vitamin-D derivatives (calcipotriene), 
tars, anthralin, salicylic acid, and retinoids. Adherence to 
these topicals has been challenged by similar factors as 
corticosteroids.33
Moderate to severe psoriasis requires systemic inter-
ventions. Phototherapy options include broadband and 
narrowband UVB, and PUVA. NBUVB is a safe and cost-
effective option. PUVA (oral or topical methoxypsoralens 
followed by UVA irradiation) is more effective than NBUVB, 
but long-term use is associated with photoaging, PUVA-
  lentigines, and increased risk of nonmelanoma skin cancer.34 
Oral psoralen is contraindicated in pregnancy.
Systemic modalities can be further categorized as 
“conventional” and “biologic”. Conventional treatments 
include methotrexate (MTX), cyclosporine A (CyA), and 
acitretin. Due to its clinical effects in skin and joints, MTX 
was the long-standing gold standard systemic agent, but is 
hepatotoxic, teratogenic, and has many drug interactions.31,35 
Traditionally, a liver biopsy is required after 1.5 g cumula-
tive dose. CyA is fast acting and efficacious, but best used 
in 3- to 4-month courses, due to its many drug interactions 
and association with nephrotoxicity, hypertension, and pos-
sibly lymphoma. Acitretin, a retinoid, differs from MTX and 
CyA by not immunosuppressing the individuals; however its 
teratogenic potential considerably limits the use in female of 
childbearing potential. Often ineffective as monotherapy, is 
frequently combined with phototherapy. Other side effects of 
acitretin include dyslipidemia and mucocutaneous irritation. 
Hydroxyurea, 6-thioguanine, leflunamide, and sulfasalazine 
are minimally effective, have appreciable toxicity, and are 
not considered first-line agents.35
Aside from ustekinumab, 4 biologic agents are currently 
FDA approved for psoriasis: alefacept (T-cell modulator), 
adalimumab, etanercept, and infliximab (TNF-α inhibitors). 
The TNF-α inhibitors are considered much more effective for 
skin involvement (better PASI 75 rates), as well as valued for 
their helpful role in psoriatic arthritis.16,36 Efalizumab, a T-cell 
modulator previously approved for the treatment of psoriasis, 
was recently withdrawn from the market because of concerns 
of progressive multifocal leukoencephalopathy (PML) after 
4 cases were reported.37 A brief summary that highlights key 
points of these agents is depicted in Table 3.
It is important to note that combination, rotational, and 
sequential therapies are frequent approaches in the treatment 
of psoriasis.2 Combining agents allows the treating physi-
cian not only to exploit synergistic effects, but also avoid 
otherwise toxic doses necessaries to achieve clearance in 
monotherapeutic regimens.38 Even though single-agent thera-
pies may have lower costs and better chance for compliance, 
more often than not, a single modality will not be sufficient 
to reach all expectations (such as complete skin clearance, 
psoriatic arthritis control when applicable, improved quality 
of life, low rate of adverse events).38
Unmet needs
Current therapeutic options offer patients with moderate 
to severe psoriasis the opportunity to achieve reasonable 
clinical outcomes.39 Nevertheless, standard treatments are 
associated with long-term toxicity, side effects, and incon-
venience, and biologics are fairly new, hence more time is 
essential to support the current evidence on efficacy and 
safety.39,40
Studies have yet to determine whether newer treatments 
satisfy patients’ needs. Future agents should meet various 
specifications in order to increase adherence, and consequently, 
total psoriasis control. A more convenient administration 
schedule/route, enhanced long-term efficacy and safety 
profiles, cost-effectiveness, and tolerability, are among the 
desirable characteristics that future agents must fulfill. In 
many cases, efficacy in psoriatic arthritis and nail psoriasis 
is also desired.
Clinical evidence 
with ustekinumab in psoriasis
Ustekinumab (Stelara®; Centocor, Inc) is a fully human mono-
clonal antibody targeting IL-12/23. It does so by binding to 
their shared p40 subunit, therefore blocking the interaction 
with their cognate receptors.41 This agent thus targets Th1 
and Th17 arms of immunity, both of which we now know Core Evidence 2010:5 16
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are key parts in the immunopathogenesis of psoriasis. It is 
administered as a subcutaneous injection.
A Biologic License Application (BLA) for ustekinumab 
was accepted by the US Food and Drug Administration 
(FDA) in February 2008. In June 2008, during an FDA 
advisory committee meeting, an expert panel unanimously 
recommended approval, but extended the review period 
until December due to concerns of the long-term safety 
data. On December 2008, the FDA issued a Complete 
Response letter for ustekinumab’s BLA requesting addi-
tional information, which was then followed on May 2009 
by a 3-month extension in the review timeline in order to 
establish the product’s shelf life. Ustekinumab was approved 
by the FDA for its use in the United States for moderate-to-
severe psoriatic patients in September 2009. It has also been 
approved in Canada and Europe for the same indication and 
currently is also being evaluated for Crohn’s disease and 
psoriatic arthritis.
Efficacy
Phase II data
In an initial phase II trial evaluating the safety and efficacy 
of single and multiple doses of ustekinumab, 320 patients 
with moderate-to-severe plaque psoriasis underwent 
randomization to receive ustekinumab or placebo.41 Par-
ticipants in this double-blind, placebo-controlled, crossover 
trial were randomly assigned to 5 groups, 64 patients each, 
receiving placebo or 1 of 4 doses of ustekinumab (one 
45 mg dose, one 90 mg dose, four weekly 45 mg doses, or 
four weekly 90 mg doses). At week 16, patients in the active 
treatment group with a PGA  3 received one additional 
injection of their originally assigned dose, and at week 20, 
patients in the placebo group crossed over to receive one 
90 mg dose of the study drug. No additional or maintenance 
therapy was given.
Efficacy assessed at week 12 (primary endpoint) revealed 
statistically significant PASI 75 scores for all groups, achiev-
ing 52% (45 mg × 1), 59% (90 mg × 1), 67% (45 mg × 4) 
and 81% (90 mg × 4) in the ustekinumab group, as compared 
with 2% in the control group. Responses were maintained 
through week 24 and then started deteriorating. Clinical 
responses were supported by the substantial improvements 
observed in the DLQI in all treatment groups. Efficacy in 
those patients who crossed over to the treatment group at 
week 20 to receive one 90 mg dose mirrored the improve-
ments observed in individuals originally assigned to the one 
90 mg dose at baseline. Serious adverse events were not 
statistically different from control.
Table 3 Key points of biologic agents approved for the treatment of psoriasis49–57
Biologic Mechanism of action Administration Efficacy as PASI 75 
(phase III trials)
Particular safety issues Comment
Alefacept Recombinant fusion 
protein. Inhibits CD2  
from interacting with 
LFA-3
15 mg IM qw for 
12 weeks, stop 
12 weeks, restart 
another 12 weeks
At week 14, 21% 
(Lebwohl et al51)
Lymphopenia (decrease  
in CD4 count)
Low rate of responders. 
Patients who do 
respond, enjoy a long-
term psoriasis remission 
and one of the best 
safety profiles among 
biologics
Adalimumab Fully human monoclonal 
antibody. Binds soluble  
and transmembrane  
TNF-α
80 mg SC loading  
dose, then 40 mg  
SC qow
At week 16, 71% 
(Menter et al53)
Injection site reactions, 
reactivation of TB, 
demyelinating disorders,  
and contraindicated  
in CHF
Balance between efficacy 
and safety. Convenient 
dosing schedule
Etanercept Receptor antibody fusion 
protein. Binds soluble  
TNF-α and lymphotoxin
50 mg SC biw for 
12 weeks, followed by 
50 mg qw
At week 12, 49%  
(Papp et al54)
Injection site reactions, 
reactivation of TB, 
demyelinating disorders,  
and contraindicated  
in CHF
Balance between efficacy 
and safety. Has been 
evaluated for pediatric 
psoriasis
Infliximab Chimeric monoclonal 
antibody. Binds soluble  
and transmembrane  
TNF-α
5 mg/kg IV at weeks  
0, 2, 6, and followed  
by q8w
At week 10, 80%  
(Reich et al56)
Infusion reactions, 
reactivation of TB, 
demyelinating disorders,  
and contraindicated  
in CHF
Rapid disease control. 
Used for unstable 
conditions such as 
erythrodermic or 
pustular psoriasis
Abbreviations: PASI, Psoriasis Area and Severity Index; IM, intramuscular; SC, subcutaneous; IV, intravenous; qw, once weekly; qow, every other week; biw, twice weekly; q8w, 
every 8 weeks. TB, tuberculosis; CHF, congestive heart failure.Core Evidence 2010:5 17
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All the data suggested a dose and/or schedule dependency 
that needed to be further explored. Consequently, the success 
of this trial paved the way for the development of phase III 
trials evaluating the therapeutic potential of ustekinumab 
for psoriasis.
Phase III data
PHOENIX 1 and PHOENIX 2 were the parallel studies 
designed for this purpose. Both multicenter, randomized, 
double-blind, placebo-controlled phase III trials shared simi-
lar objectives and methods, and elicited comparable efficacy 
and safety data. Analysis was done using non-responder 
imputation (NRI). For the purpose of this evidence-based 
review, data retrieved from these studies will be analyzed 
independently.
Eligibility criteria for both phase III trials were very 
similar to the ones described for their phase II predecessor. 
Men and women aged 18 years or older were eligible if they 
had a diagnosis of plaque psoriasis for at least 6 months, a 
baseline PASI score of 12 or higher, at least 10% body surface 
area involvement, and were candidates for phototherapy or 
systemic therapy. Patients were ineligible if they had non-
plaque forms of psoriasis, had a recent local or systemic 
infection, had a known malignancy (except treated basal 
cell skin cancer or squamous cell skin cancer for at least 
5 years), had ever received treatment with any anti IL-12/23 
agent, had received biological or investigational agents within 
the previous 3 months (or 5 drug’s half-lives), had received 
conventional systemic psoriasis therapy or phototherapy 
within the previous 4 weeks, or had received topical psoriasis 
treatment within the previous 2 weeks. Subjects with active 
tuberculosis (TB) were ineligible; however those with latent 
TB could be enrolled if TB prophylaxis was initiated before 
or simultaneous to the first administration of study agent.
PHOENIX 1 comprised 766 patients, lasted 76 weeks, and 
was divided into 3 stages: a placebo-controlled (weeks 0–12) 
stage, a placebo crossover and active treatment (weeks 
12–40), and a randomized withdrawal stage (weeks 40–76).42 
The primary endpoint was the proportion of PASI 75 respond-
ers at week 12. The study design allowed the investigators to 
assess not only the effects of this novel agent in comparison 
to a control group, but also long-term efficacy, evaluate pos-
sible escalation dose in partial responders, duration of the 
therapeutic effect after drug withdrawal, and efficacy when 
re-treating. Parameters selected to assess efficacy included 
PASI, PGA, and DLQI.
At the beginning of stage 1, subjects were randomized 
into 3 arms (1:1:1) to receive ustekinumab 45 mg (n = 255) 
or 90 mg (n = 256) at weeks 0 and 4 and then every 12 weeks, 
or placebo (n = 255) at weeks 0 and 4, and then crossover to 
ustekinumab at week 12. In the crossover stage, patients were 
randomized 1:1 in the same fashion as the original treatment 
groups (either 45 mg or 90 mg), receiving loading doses 
at week 12 and 16, followed by injections every 12 weeks. 
Then, at stage 3 (week 40), patients initially randomized to 
the treatment groups who had achieved PASI 75 at weeks 28 
and 40 were re-randomized to either continue their therapy 
regimen or were withdrawn from active treatment (assigned 
to placebo). The objective of this withdrawal stage was to 
evaluate the duration of the therapeutic effect. Once these 
patients lost 50% of their PASI improvement, they would be 
re-treated (to evaluate re-treatment).
PASI scores in all groups were reevaluated at weeks 28 
and 40. Those individuals considered non-responders (less 
than 50% improvement in their PASI scores from baseline 
to week 28) discontinued the study agent. Those considered 
partial responders (PASI scores improvements between 50% 
and 74%) were adjusted to a dosing interval of every 8 weeks. 
Those considered responders (PASI improvements of 75% 
or more from baseline to weeks 28 and 40) were kept in the 
same dosing interval (every 12 weeks).
Baseline randomization was stratified by 3 different 
parameters, including investigational site, weight (90 kg 
or 90 kg), and number of conventional systemic therapies 
to which patients had an inadequate response, intolerance, or 
contraindication (3 or 3). These led to demographics and 
clinical characteristics well balanced across treatment groups 
at baseline. Randomization at week 40 was also stratified by 
investigational site and baseline weight (90 kg or 90 kg).
At week 12 (primary endpoint), 67.1% of the 45 mg group, 
66.4% of the 90 mg group, and 3.1% of the placebo group 
achieved PASI 75 (P  0.0001 for both treatment groups 
compared to placebo). Subjects receiving ustekinumab 
experienced a rapid onset of the clinical effects, with PASI 
50 by week 2. Other parameters such as the PGA at week 
12 also showed similar clinical outcomes, with subjects 
achieving a “cleared or minimal” status 60.4% in the 45 mg 
group, 61.7% in the 90 mg group, and 3.9% in the placebo 
group (P  0.0001 for both treatment groups compared to 
placebo). Enhanced efficacy was observed throughout the 
active treatment phase, with maximum efficacy observed at 
week 24 for both dosing regimens (PASI 75 in 76.1% and 
85% of the 45 mg and 90 mg groups respectively). Similar 
outcomes were obtained in subjects originally assigned to 
placebo, after crossing over to active treatment at week 12. 
Psoriasis improvements, varying from PASI 50, PASI 75, and Core Evidence 2010:5 18
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PASI 90, were seen in ustekinumab-treated patients at weeks 
12 and 28, proving itself superior to placebo.
After re-randomization to maintenance/withdrawal at 
week 40, maintenance of PASI 75 was better among individu-
als receiving maintenance ustekinumab than in individuals 
withdrawn from treatment, up until 1 year of therapy. In 
the maintenance group PASI scores were steady all the 
way through week 76, whereas in the withdrawal group 
PASI scores began to progressively deteriorate by week 
44 (16 weeks after withdrawal), accelerating after week 52 
(24 weeks after withdrawal). The median time to loss of PASI 
75 after withdrawal was about 15 weeks.
Per protocol, withdrawn patients were retreated at their 
original dose when they lost 50% of their baseline PASI 
improvement (loss of therapeutic effect). 195 patients 
re-  initiated therapy. Among these, 85.6% regained PASI 
75 scores after 12 weeks of restarting ustekinumab.
Improvements in PASI scores were paralleled by the 
DLQI. DLQI scores of 0 or 1, meaning no negative impact 
of psoriasis on the patients’ quality of life, were achieved by 
53.1% in the 45 mg group, 52.4% in the 90 mg group, and 6% 
in the placebo group at week 12. These values were constant 
until the end of the study in patients receiving maintenance 
therapy, as opposed to the worsening reflected in the DLQI 
scores of patients withdrawn from ustekinumab.
The second phase III trial, PHOENIX 2, comprised of 
1230 patients, lasted 52 weeks, and was divided into 3 stages: 
a placebo-controlled (weeks 0–12) stage, a placebo crossover 
and active treatment (weeks 12–28), and a randomized dose 
intensification stage (week 28–52).43 The primary endpoint 
was the proportion of PASI 75 responders at week 12. The first 
two stages were identical to their equivalents in PHOENIX 
1, with the exception that the second stage in this trial was 
shortened to 28 weeks.
Like PHOENIX 1, at the beginning of the study subjects 
were randomized into 3 arms (1:1:1) to receive ustekinumab 
45 mg (n = 409) or 90 mg (n = 411) at weeks 0 and 4 and then 
every 12 weeks, or placebo (n = 410) at weeks 0 and 4, and 
then crossover to ustekinumab at week 12. The same baseline 
stratification design applied in PHOENIX 1 was used in this 
study. In the crossover stage, patients were randomized 1:1 
in the same fashion as the original treatment groups (either 
45 mg or 90 mg), receiving loading doses at week 12 and 
16, followed by injections every 12 weeks. Then at stage 3 
(week 28), those individuals with PASI  50 (considered 
non-responders) discontinued the study agent; patients ini-
tially randomized to the treatment groups who had achieved 
PASI  50 but  75 (partial responders), were re-randomized 
to either continue their therapy regimen or adjust the dosing 
schedule to every 8 weeks; and individuals with PASI  75 
continued on their 12-week schedule.
The second randomization at week 28, intended for dose 
intensification, permitted the investigation of an objective 
not previously explored: the number of visits with PASI 
75 between weeks 28 and 52 for the two different dosing 
  schedule groups (8 vs 12 weeks). Stratification by investi-
gational site and baseline weight (90 kg or 90 kg) was 
applied.
At week 12 (primary endpoint), 66.7% of the 45 mg 
group, 75.7% of the 90 mg group, and 3.7% of those receiv-
ing placebo achieved PASI 75 (P  0.0001 for both treat-
ment groups compared to placebo). Similarly, PGA revealed 
clinical outcomes with subjects achieving a “cleared or 
minimal” status of 68.0% in the 45 mg group, 73.5% in the 
90 mg group, and 4.9% in the placebo group (P  0.0001 
for both treatment groups compared to placebo). Enhanced 
efficacy was observed throughout the active treatment phase, 
with maximum efficacy observed at week 20 for both   dosing 
regimens (PASI 75 in 74.9% and 83.5% of the 45 mg and 
90 mg groups, respectively). Similar outcomes were obtained 
in placebo-assigned patients’ crossing over to treatment at 
week 12. Like before, psoriasis improvements, varying from 
PASI 50, PASI 75, and PASI 90, were seen in the majority of 
the ustekinumab-treated patients at week 12 and 28.
At week 28, partial responders were identified and 
re-randomized for dose intensification. Partial responders 
(22.7% in the 45 mg group and 15.8% in the 90 mg group) 
favored higher bodyweight, more severe PGA scores, higher 
incidence of psoriatic arthritis, and higher likelihood of pre-
ceding failure with at least one systemic agent, in comparison 
to responders to 12-weekly dosing. Predictors of partial 
response were narrowed to treatment with ustekinumab 
45 mg, higher bodyweight, inadequate response to at least 
one biological agent, longer duration of psoriasis, and history 
of psoriatic arthritis. In addition, partial responders had lower 
serum drug levels at week 28 than responders, suggesting a 
drug level/clinical response relationship.
Dosing intensification resulted in an increased serum 
drug concentration. Partial responders receiving ustekinumab 
45 mg every 8 weeks did not evidence greater efficacy that 
those on the 12-weekly schedule, whereas with 90 mg every 
8 weeks, a greater number of visits with PASI 75 responses, 
and higher PASI 75 rates per se, were obtained than with 
12-weekly dosing.
A sustained clinical improvement was observed through 
the end of the study in those individuals that reached PASI Core Evidence 2010:5 19
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75 scores by week 28. At week 52, the median percentage 
improvement from baseline in PASI was 95.3% in the 45 mg 
group and 95.6% in the 90 mg group.
Promising evidence with a similar agent has been reported 
in a phase II trial. ABT-874 (Abbott Laboratories) is a fully 
human monoclonal antibody that targets IL-12/23, thus 
working in a similar fashion as ustekinumab. The available 
literature reports PASI 75 scores at week 12 above 90% 
(depending on the dosage evaluated) with a well toler-
ated safety profile.44 It is currently undergoing phase III 
investigations and is not yet approved by the FDA for any 
indication.
Phase II data for psoriatic arthritis
Psoriatic arthritis (PsA) prevalence among patients with 
psoriasis varies widely, and it has been estimated from 
6% to 39%.5 Data suggest that IL-12 and IL-23 have 
an important role in the pathogenesis of PsA and other 
arthritides.45,46
A multicenter, randomized, double-blind, placebo-
  controlled phase II trial evaluating the efficacy and safety 
of ustekinumab for PsA was recently published.47 Although 
detailed description of this trial goes beyond the scope of 
this review, is crucial to highlight the overall study design 
and results. 146 patients with active PsA underwent 1:1 
randomization to receive ustekinumab or placebo. Subjects 
assigned to the ustekinumab group received 63 mg or 90 mg 
subcutaneously (SC) weekly for 4 weeks (weeks 0 to 3) fol-
lowed by placebo injections on weeks 12 and 16; patients 
assigned to the control group received placebo injections at 
weeks 0 to 3, followed by ustekinumab 63 mg SC at weeks 
12 and 16. A filtration procedure implemented during dose 
preparation led to the dose change from 90 mg to 63 mg. The 
primary endpoint was American College of Rheumatology 
(ACR) 20 response at week 12. Participants were followed 
up to week 36.
Men and women aged 18 years or older were eligible if 
they had active PsA (defined as 3 or more swollen joints and 
3 or more tender joints, and either C-reactive protein (CRP) 
of 15 mg/L or greater or morning stiffness for at least 45 min) 
for at least 6 months. Patients also had to have active plaque 
psoriasis, and an unsatisfactory response to DMARDs, 
NSAIDs, anti-TNF agents, or a combination of these. If 
subjects were on a stable course of therapy of MTX (up to 
25 mg/week), corticosteroids (up to 10 mg/day of prednisone 
or equivalent), NSAIDs, or a combination of these drugs, 
they were allowed to continue their regimen. Patients were 
ineligible if they had received biological or investigational 
agents within the previous 3 months, had received conven-
tional systemic psoriasis therapy or phototherapy within the 
previous 4 weeks, or had received topical psoriasis treatment 
within the previous 2 weeks.
Parameters selected to assess efficacy included ACR 
criteria, Disease Activity Index score (DAS) 28, PASI, PGA, 
DLQI, and Health Assessment Questionnaire (HAQ) dis-
ability index. ACR score assesses multiple disease criteria, 
and evaluates percentage improvement of 20%, 50% and 
70% (ACR 20, ACR 50, and ACR 70) from baseline. DAS 
28 is a derived index that combines tender and swollen joint 
counts (n = 28), CRP, and patient’s global assessment of 
disease activity.
Efficacy assessed at week 12 (primary endpoint) revealed 
ACR 20 scores for the active treatment group of 42% (32 of 
76), as compared with 14% (10 of 70) in the control group 
(P = 0.0002). Also, more patients in the ustekinumab group 
achieved ACR 50 (25% [19/76] vs placebo 7% [5/70]) and 
ACR 70 (11% [8/76] vs placebo 0) responses at week 12. 
All ACR responses in the active treatment group peaked 
at weeks 16 to 20, and then decreased slowly to week 36. 
After placebo patients crossed over to ustekinumab at week 
12, they achieved similar ACR 20 responses to those in the 
treatment group at week 24 (51%, 28/55), week 28 (45%, 
24/53), and at week 36 (42%, 21/50). Clinical responses 
were supported by the substantial improvements observed 
in the DLQI and HAQ disability index at week 12 in the 
treatment group. Psoriasis measures were also reduced with 
ustekinumab treatment.
Results from this trial show that ustekinumab is effica-
cious for the treatment of active PsA. Larger and longer 
studies are needed to further characterize ustekinumab for 
the treatment of this condition.
Safety and tolerability
Unlike efficacy data (analyzed based on assigned treatment 
group), safety data were analyzed based on actual treatment 
and included all patients who had received at least one dose 
of ustekinumab.42,43 Since both PHOENIX 1 and 2 reported 
similar safety data, when possible, they are presented together 
(safety data from the phase II PsA trial were not included 
in this section).
Ustekinumab was generally well tolerated at both doses 
(45 and 90 mg) and dosing schedules (every 8 and 12 weeks). 
The majority of adverse events were mild, nonserious and 
did not require treatment adjustment. The rate and types of 
adverse events were much the same across all groups (treat-
ment and placebo) throughout the different phases of both Core Evidence 2010:5 20
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studies, although absolute event rates differed across study 
phases consistent with different lengths of follow up. An 
  exception to this occurred during the dose intensification 
phase in PHOENIX 2, where adverse events were more fre-
quent in patients receiving treatment every 8 weeks (72.7%) 
than in those receiving treatment every 12 weeks (63%). 
  Paradoxically, serious adverse events were more frequent in 
the 12-weekly (7.4%) than in the 8-weekly group (2.6%). By 
the end of the trials, no dose response was seen in the rates 
of adverse events, serious events, or events leading to study 
agent discontinuation. The most commonly reported adverse 
events were upper respiratory tract infections, nasopharyn-
gitis, headaches, and arthralgias. The most common serious 
events included infections, malignancies, and cardiovascular 
events.42,43
Rates of laboratory abnormalities were low and gener-
ally similar between treatment groups and placebo groups. 
Ustekinumab showed no effect on glucose, hemoglobin 
A1c, neutrophil counts, or D-dimer levels. Antibodies to 
ustekinumab were found in 5.1% of the patients by the end 
of week 76 (PHOENIX 1), and in 5.4% by the end of week 
52 (PHOENIX 2). They were mostly low titer. Injection site 
reactions were infrequent (1% for ustekinumab, and 0.4% 
for placebo), probably due to the scarcity of the injections. 
No anaphylactic or serum-sickness-like reactions were 
reported.
Economic evidence  
and resource utilization
There are no studies yet that include an economic evalu-
ation of ustekinumab in psoriasis. The drug was recently 
approved in Canada (December 2008) and in Europe by 
the European Medicines Agency (EMEA) (January 16, 
2009). More recently, the drug was approved by the FDA 
for patients with moderate to severe forms of psoriasis 
(September 25, 2009).
Because this drug represents the first agent developed 
among its class, it’s difficult to predict its overall impact. 
Ustekinumab’s clinical trials have shown an apparent better 
risk/benefit ratio that, if supported by future more powerful 
data, may possibly propel this novel agent to become an even 
more attractive therapeutic alternative. Its infrequent dosing 
schedule, and the possibility of added benefit for patients with 
concomitant psoriatic arthritis, further increase the potential 
of the drug. It will be important to determine in future studies 
the drug’s effect on reductions in direct and indirect costs 
of the disease, such as visits to physicians, work days lost to 
the disease or treatments, etc.
Patient group/population
Ustekinumab trials have shown efficacy in men and women, 
aged 18 years or older, with a diagnosis of chronic moder-
ate to severe plaque psoriasis. Due to the profile of the 
patients that participated in the phase III trials (eg, elevated 
bodyweight, failed prior systemic therapies), it seems that 
this drug could potentially benefit patients with recalcitrant 
psoriasis who have failed previous therapeutic regimens, 
including conventional and biologic agents. In addition, 
patients with concomitant psoriatic arthritis may benefit 
from it as well.
Intermittently, patients with refractory psoriasis have 
demanded from their treating physicians trials of differ-
ent drugs, combining and rotating agents arbitrarily in the 
search of a reasonable improvement. Although not gener-
ally resulting in satisfactory clinical outcomes, toxicities 
and side effects can arise, further complicating the picture. 
An agent with efficacy rates as promising as ustekinumab’s 
might represent a valuable alternative for these challenging 
cases. What is more, so far its safety profile has shown to be 
relatively benign.
Clinical potential
At the primary endpoint (week 12), ustekinumab has suc-
cessfully established its superiority over placebo and over 
currently available psoriasis therapies. Not only have more 
patients achieved PASI 75 scores than with other biologics, 
but also its rapid onset of action and better dosing profile 
makes this agent a potentially valuable alternative for pso-
riatic patients. Moreover, the duration of the phase III trials 
demonstrated ustekinumab’s sustained long-term clinical 
responses (up to 76 weeks of treatment). All analyses were 
done using NRI, yielding reliable, if not underestimated, 
efficacy rates.48
Patients with refractory psoriasis that have failed to 
respond to other systemic and/or biologic agents seem to be 
the kind of cases that could potentially benefit most from this 
novel compound. Once additional data become available, 
the target population for this drug will be furthered defined. 
Because of its convenient dosing schedule as an infrequent 
monotherapeutic agent, it may translate into lower costs and 
better chance for compliance.
Additional investigations evaluating long-term effi-
cacy, and more specifically safety data, are needed before 
ustekinumab can become a major player in the biologics 
market. Assessment of clinical effects on psoriatic arthri-
tis might be part of the objectives in future ustekinumab 
studies.Core Evidence 2010:5 21
Ustekinumab for psoriasis Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Disclosure
Dr Gordon has received honoraria and research support from 
Centocor, the manufacturers of ustekinumab.
References
  1.  Schon MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352: 
1899–1912.
  2.  van de Kerkhof PC. Consistent control of psoriasis by continuous 
long-term therapy: the promise of biological treatments. J Eur Acad 
Dermatol Venereol. 2006;20:639–650.
  3.  Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 
cytokine, mediates IL-23-induced dermal inflammation and acanthosis. 
Nature. 2007;445:648–651.
  4.  Torti DC, Feldman SR. Interleukin-12, interleukin-23, and psoriasis: 
current prospects. J Am Acad Dermatol. 2007;57:1059–1068.
  5.  Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic 
arthritis in the population of the United States. J Am Acad Dermatol. 
2005;53:573–577.
  6.  Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome 
in patients with psoriasis: a hospital-based case-control study. Br J 
Dermatol. 2007;157:68–73.
  7.  Chen YJ, Wu CY, Shen JL, et al. Psoriasis independently associated with 
hyperleptinemia contributing to metabolic syndrome. Arch Dermatol. 
2008;144:1571–1575.
  8.  Nijsten T, Wakkee M. Complexity of the association of between   psoriasis 
and comorbidities. J Invest Dermatol. 2009;129:1601–1603.
  9.  Gupta MA, Gupta AK. Depresion and suicidal ideation in dermatology 
patients with acne, alopecia areata, atopic dermatitis and psoriasis. 
Br J Dermatol. 1998;139:846–850.
10.  Russo PA, Ilchef R, Cooper AJ. Psychiatric morbidity in psoriasis: a 
review. Australas J Dermatol. 2004;45:155–159; quiz 160–161.
11.  Magin PJ, Pond CD, Smith WT, Watson AB, Goode SM. A 
cross-  sectional study of psychological morbidity in patients with 
acne, psoriasis and atopic dermatitis in specialist dermatology 
and general practices. J Eur Acad Dermatol Venereol. 2008;22: 
1435–1444.
12.  Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. 
The impact of psoriasis on quality of life: results of a 1998 National 
Psoriasis Foundation patient-membership survey. Arch Dermatol. 
2001;137:280–284.
13.  Smith CH, Anstey AV , Barker JN, et al. British Association of Derma-
tologists guidelines for use of biological interventions in psoriasis 2005. 
Br J Dermatol. 2005;153:486–497.
14.  Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. 
Psoriasis causes as much disability as other major medical diseases. J 
Am Acad Dermatol. 1999;41:401–407.
15.  Nair RP, Stuart PE, Nistor I, et al. Sequence and haplotype analysis sup-
ports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet. 
2006;78:827–851.
16.  Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care 
for the management of psoriasis and psoriatic arthritis: Section 
1. Overview of psoriasis and guidelines of care for the treat-
ment of psoriasis with biologics. J Am Acad Dermatol. 2008;58: 
826–850.
17.  Krueger G, Ellis CN. Psoriasis – recent advances in understanding its 
pathogenesis and treatment. J Am Acad Dermatol. 2005;53:S94–S100.
18.  Somani AK, Yang MF, Cooper KD, McCormick TS. Cytokines and 
psoriasis. When cytokines become “pathokines”. G Ital Dermatol 
Venereol. 2007;142:679–690.
19.  Nickoloff BJ. Cracking the cytokine code in psoriasis. Nat Med. 
2007;13:242–244.
20.  Reddy M, Davis C, Wong J, Marsters P, Pendley C, Prabhakar U. 
Modulation of CLA, IL-12R, CD40L, and IL-2Ralpha expression and 
inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 
1275. Cell Immunol. 2007;247:1–11.
21.  Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epider-
mal hyperplasia by TNF inhibition is associated with reduced Th17 
responses. J Exp Med. 2007;204:3183–3194.
22.  Guttman-Yassky E, Lowes MA, Fuentes-Duculan J, et al. Major 
differences in inflammatory dendritic cells and their products dis-
tinguish atopic dermatitis from psoriasis. J Allergy Clin Immunol. 
2007;119:1210–1217.
23.  Zaba LC, Krueger JG, Lowes MA. Resident and “inflammatory” den-
dritic cells in human skin. J Invest Dermatol. 2009;129:302–308.
24.  Nickoloff BJ, Qin JZ, Nestle FO. Immunopathogenesis of psoriasis. 
Clin Rev Allergy Immunol. 2007;33:45–56.
25.  Nickoloff BJ, Xin H, Nestle FO, Qin JZ. The cytokine and chemokine 
network in psoriasis. Clin Dermatol. 2007;25:568–573.
26.  Toichi E, Torres G, McCormick TS, et al. An anti-IL-12p40 antibody 
down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in 
psoriasis. J Immunol. 2006;177:4917–4926.
27.  Nair RP, Ruether A, Stuart PE, et al. Polymorphisms of the IL12B 
and IL23R genes are associated with psoriasis. J Invest Dermatol. 
2008;128:1653–1661.
28.  Henseler T, Schmitt-Rau K. A comparison between BSA, PASI, PLASI 
and SAPASI as measures of disease severity and improvement by ther-
apy in patients with psoriasis. Int J Dermatol. 2008;47:1019–1023.
29.  Gordon KB. Clinical Outcomes Measurements. In Gordon KB, 
Ruderman EM, eds. Psoriasis and Psoriatic Arthritis, An Integral 
Approach. New York: Springer; 2005:125–128.
30.  Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and 
Severity Index, Psoriasis Global Assessment, and Lattice System Phy-
sician’s Global Assessment. J Am Acad Dermatol. 2004;51:563–569.
31.  Menter A, Griffiths CE. Current and future management of psoriasis. 
Lancet. 2007;370:272–284.
32.  Strowd LC, Yentzer BA, Fleischer AB Jr, Feldman SR. Increasing 
use of more potent treatments for psoriasis. J Am Acad Dermatol. 
2008;60:478–481.
33.  Feldman SR, Horn EJ, Balkrishnan R, et al. Psoriasis: improving adher-
ence to topical therapy. J Am Acad Dermatol. 2008;59:1009–1016.
34.  Nijsten TE, Stern RS. The increased risk of skin cancer is persistent 
after discontinuation of psoralen+ultraviolet A: a cohort study. J Invest 
Dermatol. 2003;121:252–258.
35.  Strober BE, Siu K, Menon K. Conventional systemic agents for pso-
riasis. A systematic review. J Rheumatol. 2006;33:1442–1446.
36.  Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the 
management of psoriasis and psoriatic arthritis: Section 2. Psoriatic 
arthritis: overview and guidelines of care for treatment with an emphasis 
on the biologics. J Am Acad Dermatol. 2008;58:851–864.
37.  FDA Medwatch for Efalizumab. Feb 2009. URL: www.fda.gov
38.  Lebwohl M, Menter A, Koo J, Feldman SR. Combination therapy to 
treat moderate to severe psoriasis. J Am Acad Dermatol. 2004;50: 
416–430.
39. Nijsten T, Margolis DJ, Feldman SR, Rolstad T, Stern RS. Tradi-
tional systemic treatments have not fully met the needs of psoriasis 
patients: results from a national survey. J Am Acad Dermatol. 2005;52: 
434–444.
40.  Papp KA. The long-term efficacy and safety of new biological therapies 
for psoriasis. Arch Dermatol Res. 2006;298:7–15.
41.  Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 
monoclonal antibody for the treatment of psoriasis. N Engl J Med. 
2007;356:580–592.
42.  Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of 
ustekinumab, a human interleukin-12/23 monoclonal antibody, in 
patients with psoriasis: 76-week results from a randomised, double-
blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371: 
1665–1674.
  43.  Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of 
ustekinumab, a human interleukin-12/23 monoclonal antibody, in 
patients with psoriasis: 52-week results from a randomised, double-
blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371: 
1675–1684.Core Evidence 2010:5
Core Evidence
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/core-evidence-journal
Core Evidence is an international, peer-reviewed open-access journal 
evaluating the evidence underlying the potential place in therapy of 
drugs throughout their development lifecycle from preclinical to post-
launch. The focus of each review is to evaluate the case for a new drug 
or class in outcome terms in specific indications and patient groups. 
The manuscript management system is completely online and includes 
a very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
22
Krulig and Gordon Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
44.  Kimball AB, Gordon KB, Langley RG, Menter A, Chartash EK, 
Valdes J. Safety and efficacy of ABT-874, a fully human interleukin 
12/23 monoclonal antibody, in the treatment of moderate to severe 
chronic plaque psoriasis: results of a randomized, placebo-controlled, 
phase 2 trial. Arch Dermatol. 2008;144:200–207.
45.  Kim M, Min S, Cho M, et al. The role of IL-12 in inflammatory activ-
ity of patients with rheumatoid arthritis (RA). Clin Exp Immunol. 
2000;119:175–181.
46.  Szodoray P, Alex P, Chapell-Woodward CM, et al. Circulating cytokines 
in Norwegian patients with psoriatic arthritis determined by a multiple 
cytokine array system. Rheumatology. 2007;46:417–425.
47.  Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human 
interleukin 12/23 monoclonal antibody, for psoriatic arthritis: Ran-
domised, double-blind, placebo-controlled, crossover trial. Lancet. 
2009;373:633–40.
48.  Heritier SR, Gebski VJ, Keech AC. Inclusion of patients in clinical trial 
analysis: the intention-to-treat principle. Med J Aust. 2003;179:438–440.
49.  Tzu J, Krulig E, Cardenas V , Kerdel FA. Biological agents in the treat-
ment of psoriasis. G Ital Dermatol Venereol. 2008;143:315–327.
50.  Brimhall AK, King LN, Licciardone JC, Jacobe H, Menter A. Safety and 
efficacy of alefacept, efalizumab, etanercept and infliximab in treating 
moderate to severe plaque psoriasis: a meta-analysis of randomized 
controlled trials. Br J Dermatol. 2008;159:274–285.
51.  Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, 
Griffiths CE. An international, randomized, double-blind, placebo-
controlled phase 3 trial of intramuscular alefacept in patients with 
chronic plaque psoriasis. Arch Dermatol. 2003;139:719–727.
52.  Gordon KB, Langley RG, Leonardi C, et al. Clinical response to 
adalimumab treatment in patients with moderate to severe psoriasis: 
double-blind, randomized controlled trial and open-label extension 
study. J Am Acad Dermatol. 2006;55:598–606.
53.  Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moder-
ate to severe psoriasis: A randomized, controlled phase III trial. J Am 
Acad Dermatol. 2008;58:106–115.
54.  Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized 
controlled trial of etanercept in psoriasis: safety, efficacy, and effect of 
dose reduction. Br J Dermatol. 2005;152:1304–1312.
55.  Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, 
fatigue, and depression in psoriasis: double-blind placebo-controlled 
randomised phase III trial. Lancet. 2006;367:29–35.
56.  Reich K, Nestle FO, Papp K, et al. Infliximab induction and mainte-
nance therapy for moderate-to-severe psoriasis: a phase III, multicentre, 
double-blind trial. Lancet. 2005;366:1367–1374.
57.  Hamilton CD. Infectious complications of treatment with biologic 
agents. Curr Opin Rheumatol. 2004;16:393–398.